BioNTech's CEO, CMO prep departure to set up next-gen mRNA spinout

Source: https://www.fiercebiotech.com/biotech/biontechs-ceo-cmo-prep-departure-set-next-gen-mrna-company

BioNTech’s co-founders Uğur Şahin and Özlem Türeci are leaving the company to launch a new venture focused on next-generation mRNA innovations.

I speculate this reflects a natural split between what BioNTech has become and what excites them most: BioNTech is increasingly turning into a late-stage, execution-focused commercial biotech that needs strong operators to drive approvals, launches, and portfolio discipline, while the two founders may prefer to return to earlier, higher-risk mRNA platform innovation. The structure of the move supports that reading too, since they are not fully severing ties, but building a new vehicle for next-generation mRNA work while BioNTech retains an economic stake and sharpens its focus on becoming a multi-product oncology company.

Meanwhile, Biontech is tanking 17% at pre-market.